The IL-23–IL-17 cytokine signaling axis drives several chronic inflammatory diseases, including multiple sclerosis (MS), arthritis, psoriasis, and inflammatory bowel disease (IBD); and genetic inactivation or pharmacological blockade of IL-23 signaling blocks the disease development. Here, IL23A is linked to myeloid sarcoma.